The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: A randomized controlled trial

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1931-1941

  Niaura, Raymond ^a,g   Hays, J Taylor ^b   Jorenby, Douglas E ^c   Leone, Frank T ^d   Pappas, John E ^e   Reeves, Karen R ^f   Williams, Kathryn E ^f   Billing Jr , Clare B ^f  

^a BROWN UNIVERSITY   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Kentucky Medical Research Center   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g BUTLER HOSPITAL   (United States)

Author keywords

Drug therapy; Partial agonist; Smoking cessation; Varenicline

Indexed keywords

CARBON MONOXIDE; PLACEBO; VARENICLINE;

ABNORMAL THINKING; ACCIDENTAL INJURY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHARYNGITIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; QUINOXALINES; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 47949125773     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802177523     Document Type: Article

References (19)

1. Guindon GE, Boisclair D. Past, current, and future trends in tobacco use, 2nd ed. Washington (DC): The World Bank; 2003. Available at: wwwl.worldbank.org/tobacco/publications.asp [Last accessed March 1, 2007]
2. Rodgers A. Quantifying selected major risks to health. In: Campanini B, Haden A, editors. The World Health Report 2002: reducing risks, promoting healthy life. Geneva (Switzerland): World Health Organization; 2002. p.47-98
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
4. Peto R, Lopez A. Future worldwide health effects of current smoking patterns. In: Koop CE, Pearson CE, Schwartz MR, editors. Critical issues in global health. San Francisco (CA): Jossey-Bass; 2001. p. 155
5. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4-beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
6. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- andbupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8
7. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7
8. Anon. Clearing the air: how to quit smoking and quit for keeps. Publication 95-1647. Bethesda (MD): National Institutes of Health, National Cancer Institute; 1995
9. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000;45:1200-62
10. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville (MD): US Department of Health and Human Services, Public Health Service; 2000
11. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43:289-94
12. Cappelleri JC, Bushmakin AG, Baker CL, et al. Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. Curr Med Res Opin 2005;21:749-60
13. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 1998;6:331-43
14. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56
15. Tsai S-T, Cho H-J, Cheng H-S, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39
16. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; CD000031
17. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;CD000146
18. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:47-55
19. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:56-63